EUVIMEDEUVIMED entdecken
Crossref

Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy

Rosalinda Madonna, Stefania Moscato, Maria Concetta Cufaro, Damiana Pieragostino, Letizia Mattii, Piero Del Boccio, Sandra Ghelardoni, Riccardo Zucchi, Raffaele De Caterina iD

Cardiovascular Research · 22.05.2023 · 119 (5) · 1175-1189

DOI: 10.1093/cvr/cvad009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 11.01.2023. Verfasst von Rosalinda Madonna und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, Department of Pathology, University of Pisa, Via Paradisa, 56124 Pisa, Italy. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Diabetes Mellitus. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Ministero dell’Istruzione, Università e Ricerca Scientifica to De Caterina and Madonna, Mattii and Moscato, Del Boccio.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Sodium-glucose cotransporter 2 inhibitors have beneficial effects on heart failure and cardiovascular mortality in diabetic and non-diabetic patients, with unclear mechanisms. Autophagy is a cardioprotective mechanism under acute stress conditions, but excessive autophagy accelerates myocardial cell death leading to autosis. We evaluated the protective role of empagliflozin (EMPA) against cardiac injury in murine diabetic cardiomyopathy. Methods and results Male mice, rendered diabetics by one single intraperitoneal injection of streptozotocin and treated with EMPA (30 mg/kg/day), had fewer apoptotic cells (4.9 ± 2.1 vs. 1 ± 0.5 TUNEL-positive cells %, P < 0.05), less senescence (10.1 ± 2 vs. 7.9 ± 1.2 β-gal positivity/tissue area, P < 0.05), fibrosis (0.2 ± 0.05 vs. 0.15 ± 0.06, P < 0.05 fibrotic area/tissue area), autophagy (7.9 ± 0.05 vs. 2.3 ± 0.6 fluorescence intensity/total area, P < 0.01), and connexin (Cx)-43 lateralization compared with diabetic mice. Proteomic analysis showed a down-regulation of the 5′ adenosine monophosphate-activated protein kinase (AMPK) pathway and upstream activation of sirtuins in the heart of diabetic mice treated with EMPA compared with diabetic mice. Because sirtuin activation leads to the modulation of cardiomyogenic transcription factors, we analysed the DNA binding activity to serum response elements (SRE) of serum response factor (SRF) by electromobility shift assay. Compared with diabetic mice [0.5 ± 0.01 densitometric units (DU)], non-diabetic mice treated with EMPA (2.2 ± 0.01 DU, P < 0.01) and diabetic mice treated with EMPA (2.0 ± 0.1 DU, P < 0.01) significantly increased SRF binding activity to SRE, paralleled by increased cardiac actin expression (4.1 ± 0.1 vs. 2.2 ± 0.01 target protein/β-actin ratio, P < 0.01). EMPA significantly reversed cardiac dysfunction on echocardiography in diabetic mice and inhibited excessive autophagy in high-glucose-treated cardiomyocytes by inhibiting the autophagy inducer glycogen synthase kinase 3 beta (GSK3β), leading to reactivation of cardiomyogenic transcription factors.

Conclusion

Taken together, our results describe a novel paradigm in which EMPA inhibits hyperactivation of autophagy through the AMPK/GSK3β signalling pathway in the context of diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic CardiomyopathiesDiabetes MellitusMiceMaleAnimalsAMP-Activated Protein KinasesGlycogen Synthase Kinase 3 betaProteomicsMyocytes, CardiacTranscription FactorsGlucoseAutophagyBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

AutophagyConnexinsDiabetic cardiomyopathyEmpagliflozinGlycogen synthase kinase 3 betaSerum response factorSodium-glucose cotransporter Type 2 inhibitors

Substanzen

AMP-Activated Protein KinasesGlycogen Synthase Kinase 3 betaTranscription FactorsGlucoseempagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Cardiology Division, Department of Pathology, University of Pisa, Via Paradisa, 56124 Pisa, Italy.
  • Histology Division, Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56126 Pisa, Italy.
  • Department of Pharmacy, 'G. d'Annunzio' University of Chieti-Pescara, Via Colle dell'Ara, 56100 Chieti, Italy.
  • Analytical Biochemistry and Proteomics Laboratory, Center for Advanced Studies and Technology (CAST), 'G. d'Annunzio' University of Chieti-Pescara, Via Colle dell'Ara, 56100 Chieti, Italy.
  • Department of Innovative Technologies in Medicine and Dentistry, 'G. d'Annunzio' University of Chieti-Pescara, Via Colle dell'Ara, 56100 Chieti, Italy.
  • Department of Pathology, Laboratory of Biochemistry, University of Pisa, Via Savi 10, 56126 Pisa, Italy.

ORCID-Profile: Raffaele De Caterina

Förderung

  • Ministero dell’Istruzione, Università e Ricerca Scientifica to De Caterina and Madonna
  • Mattii and Moscato
  • Del Boccio

Zitieren

APA

Madonna, R., Moscato, S., Cufaro, M. C., Pieragostino, D., Mattii, L., Del Boccio, P., Ghelardoni, S., Zucchi, R., & De Caterina, R. (2023). Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy. Cardiovascular Research, 119(5), 1175-1189. https://doi.org/10.1093/cvr/cvad009

Vancouver

Madonna R, Moscato S, Cufaro MC, Pieragostino D, Mattii L, Del Boccio P, et al. Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy. Cardiovascular Research. 2023;119(5):1175-1189. doi:10.1093/cvr/cvad009

BibTeX
@article{Madonna2023,
  author = {Madonna, Rosalinda and Moscato, Stefania and Cufaro, Maria Concetta and Pieragostino, Damiana and Mattii, Letizia and Del Boccio, Piero and Ghelardoni, Sandra and Zucchi, Riccardo and De Caterina, Raffaele},
  title = {Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy},
  journal = {Cardiovascular Research},
  year = {2023},
  volume = {119},
  number = {5},
  pages = {1175--1189},
  doi = {10.1093/cvr/cvad009}
}
Kostenlos starten →